VIDEO: Data show positive effect of Axpaxli for wet AMD at 36 weeks

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Anat Loewenstein, MD, of Tel Aviv Medical Center in Israel, discusses Axpaxli for the treatment of neovascular age-related macular degeneration.
Loewenstein highlights phase 1 and phase 2 data for Axpaxli (axitinib intravitreal implant, Ocular Therapeutix) collected in the U.S. and Australia.
“This inhibitor was able to hold patients rescue-free for as long as 36 weeks,” she said.